Genetic Engineering & Biotechnology News

13 hours ago | genengnews.com | John Sterling |Daniel R Getts

Credit: Myeloid Therapeutics Imagine dedicating your life to science, only to see your work undermined by conspiracy theories and political noise. Case in point: the Trump administration recently canceled over $766 million in federal funding allocated to Moderna to develop an mRNA-based H5N1 bird flu vaccine. Despite promising early results, the program was abruptly halted. Health Secretary Robert F. Kennedy Jr., a vocal critic of mRNA, cited concerns about safety and transparency.

20 hours ago | genengnews.com | Alex Philippidis |Fay Y. Lin |Uduak Grace Thomas |Corinna Singleman

A gene therapy clinical trial for Danon disease run by Rocket Pharmaceuticals has been suspended following the death of a patient. MIT and Recursion have released Boltz-2, an open-source tool that predicts molecular binding affinity at newfound speed and accuracy, aiming to democratize commercial drug discovery. Intellia Therapeutics saw its stock nosedive late last week after a patient in its Phase III trial of the CRISPR-based therapy experienced non-lethal liver toxicity.

22 hours ago | genengnews.com | Uduak Grace Thomas

Scientists from the University of California, San Diego (UC San Diego), have published data from a study that tested the effects of a gene therapy for Alzheimer’s disease (AD) dubbed AAV9-Synapsin-promoted Cav-1 (SynCav1) in mice. The results indicate that the therapy could be an effective way to protect the brain from disease-related damage and preserve cognitive function.

1 day ago | genengnews.com | Kevin Davies |Alex Philippidis

Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy recommendations with leaders of the FDA in an extraordinary roundtable. The roundtable was conducted in front of the FDA’s recently appointed top officials—director Martin A. Makary, MD, and Vinayak (Vinay) Kashyap Prasad, MD, director of the Center for Biologics Evaluation and Research.

1 day ago | genengnews.com | John Sterling

The National Multiple Sclerosis Society (NMSS) announced a number of new funding opportunities aimed to bolster MS research and training. Support originates both from the Society and outside entities. The move comes as the White House continues to lobby Congress to significantly cut funding for public health and biomedical research in the 2026 fiscal year that begins in October.